Canada Pension Plan Investment Board bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, according to its most recent filing with the SEC. The institutional investor bought 18,700 shares of the biotechnology company’s stock, valued at approximately $630,000.

Other large investors have also recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Sarepta Therapeutics by 4,403.1% in the first quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock valued at $156,664,000 after buying an additional 5,175,193 shares during the last quarter. Camber Capital Management LLC purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $39,960,000. State Street Corp increased its stake in shares of Sarepta Therapeutics by 21.2% in the first quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock valued at $94,641,000 after buying an additional 559,342 shares during the last quarter. Pinnacle Associates Ltd. purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $10,706,000. Finally, Elk Creek Partners LLC increased its stake in shares of Sarepta Therapeutics by 77.8% in the first quarter. Elk Creek Partners LLC now owns 562,522 shares of the biotechnology company’s stock valued at $16,651,000 after buying an additional 246,059 shares during the last quarter. 65.43% of the stock is owned by hedge funds and other institutional investors.

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) opened at 39.27 on Thursday. Sarepta Therapeutics, Inc. has a 52 week low of $25.47 and a 52 week high of $63.73. The firm has a 50-day moving average of $37.65 and a 200-day moving average of $33.32. The firm’s market cap is $2.53 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. During the same quarter in the previous year, the business posted ($1.19) earnings per share. Sarepta Therapeutics’s quarterly revenue was up 350000.0% compared to the same quarter last year. On average, analysts expect that Sarepta Therapeutics, Inc. will post ($1.16) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “18,700 Shares in Sarepta Therapeutics, Inc. (SRPT) Acquired by Canada Pension Plan Investment Board” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/18700-shares-in-sarepta-therapeutics-inc-srpt-acquired-by-canada-pension-plan-investment-board/1533062.html.

SRPT has been the subject of several recent analyst reports. Janney Montgomery Scott upped their target price on shares of Sarepta Therapeutics from $65.00 to $73.00 and gave the company a “fair value” rating in a research note on Monday, July 24th. Vetr downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $36.86 target price for the company. in a research note on Monday, May 22nd. Credit Suisse Group reaffirmed an “outperform” rating and issued a $64.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 30th. Nomura reaffirmed a “buy” rating and issued a $84.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, May 23rd. Finally, Zacks Investment Research downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. Eight equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Sarepta Therapeutics presently has an average rating of “Buy” and an average target price of $61.28.

In other Sarepta Therapeutics news, CFO Sandesh Mahatme sold 50,000 shares of the business’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $2,050,000.00. Following the completion of the sale, the chief financial officer now directly owns 41,736 shares in the company, valued at approximately $1,711,176. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Edward M. Md Kaye sold 10,000 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $410,000.00. Following the sale, the director now owns 62,471 shares of the company’s stock, valued at $2,561,311. The disclosure for this sale can be found here. Insiders sold a total of 78,056 shares of company stock valued at $3,224,208 over the last quarter. 9.60% of the stock is owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.